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The response of CD1d-restricted
invariant NKT cells to microbial
pathogens and their products
Luc Van Kaer*, Vrajesh V. Parekh and Lan Wu
Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA
Invariant natural killer T (iNKT) cells become activated during a wide variety of infections.
This includes organisms lacking cognate CD1d-binding glycolipid antigens recognized by
the semi-invariant T cell receptor of iNKT cells. Additional studies have shown that iNKT
cells also become activated in vivo in response to microbial products such as bacterial
lipopolysaccharide, a potent inducer of cytokine production in antigen-presenting cells
(APCs). Other studies have shown that iNKT cells are highly responsive to stimulation by
cytokines such as interleukin-12. These findings have led to the concept that microbial
pathogens can activate iNKT cells either directly via glycolipids or indirectly by inducing
cytokine production in APCs. iNKT cells activated in this manner produce multiple
cytokines that can influence the outcome of infection, usually in favor of the host, although
potent iNKT cell activation may contribute to an uncontrolled cytokine storm and sepsis.
One aspect of the response of iNKT cells to microbial pathogens is that it is short-lived and
followed by an extended time period of unresponsiveness to reactivation. This refractory
period may represent a means to avoid chronic activation and cytokine production by
iNKT cells, thus protecting the host against some of the negative effects of iNKT cell
activation, but potentially putting the host at risk for secondary infections. These effects
of microbial pathogens and their products on iNKT cells are not only important for
understanding the role of these cells in immune responses against infections but also
for the development of iNKT cell-based therapies.
Keywords: invariant natural killer T cells, CD1d, glycolipid antigens, microbial pathogens, microbial products,
immunological unresponsiveness, immunotherapy
Introduction
The immune response to microbial pathogens is orchestrated by reciprocal interactions between
various components and cells of the innate and adaptive immune systems. While cells of the innate
immune system recognize foreign invaders via conserved receptors that bind molecular patterns
containedwithin a variety ofmicroorganisms, cells of the adaptive immune system recognize foreign
invaders via highly diverse antigen receptors that exhibit substantial pathogen-specificity. A key
aspect of the adaptive immune system is its capacity to remember prior encounters with the same
antigen, a property that forms the basis for the efficacy of vaccines. In addition to immune cells that
can be clearly labeled as belonging to the innate or adaptive arms of the immune system, studies
over the past few decades have identified several lymphocyte subsets that express antigen-specific
receptors, yet exhibit many characteristics typical of cells of the innate immune system. This family
of cells includes both B and T lineage cells and is often referred to as innate-like B and T lymphocytes
(1). Innate-like B cells include B-1a and B-1b B cells, subsets of regulatory B (Breg) cells, marginal
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zone (MZ) B cells, and innate response activator (IRA) cells.
Innate-like T cells include subsets of γδ T cells, mucosal T cells
expressing CD8αα homodimers, mucosal-associated invariant T
(MAIT) cells, and natural killer T (NKT) cells. Each of these
cell types expresses a limited repertoire of antigen-specific recep-
tors, responds rapidly to antigenic stimulation, and is unable
to induce long-lasting immunity. These cells cannot be eas-
ily categorized as innate or adaptive, and have therefore been
referred to as “inbetweeners” (2). Several of these cell types
reside at mucosal surfaces, body cavities, or entry points of
lymphoid organs, where they are one of the first cell types to
interact with pathogens, thus playing a sentinel function in the
immune system. These cells, through recognition of non-specific
innate immune signals and production of immunomodulatory
cytokines, interact with and influence the function of multiple
cell types in the innate and adaptive branches of the immune
system, and thus shape subsequent inflammatory responses and
impact disease outcomes. Such innate effector functions permit
these cells to respond rapidly during the early stage of immune
and inflammatory responses and serve as a bridge to adaptive
immunity.
In this review article, we focus on NKT cells, and particularly
the subset of NKT cells called invariant natural killer T (iNKT)
cells. These cells play a critical role in the immune response against
a variety of microbial pathogens, a topic that is described in a
number of excellent review articles (3–5). Here, we focus on the
mechanisms of iNKT cell activation by microbial pathogens and
the dynamics of the ensuing iNKT cell response.
General Properties and Functions of iNKT
Cells
Natural killer T cells are a subset of T lymphocytes that recognize
lipid and glycolipid antigens when bound with the major histo-
compatibility complex (MHC) class I-related protein CD1d (6–9).
Because the nomenclature of NKT cells and related cell types is
confusing, we refer the reader to an opinion article on this topic
(10). Two subsets of NKT cells have been identified: type 1 or
iNKT cells express a semi-invariant T cell receptor (TCR), whereas
type 2 or variant NKT (vNKT) cells express more diverse, yet
oligoclonal TCRs (10).
Murine iNKT cells express Vα14-Jα18 chains paired with
either Vβ8.2, -7, or -2 chains, and human iNKT cells express
homologous Vα24–Jα18 chains paired with Vβ11. These cells
also express a variety of receptors such as NK1.1 (expressed in
some mouse strains) and members of the Ly49 family that are
characteristic of the natural killer (NK) cell lineage. iNKTcells also
express surface markers such as CD25, CD44, and CD69, which
are characteristic of activated and memory T cells. The majority
of iNKT cells also express the co-receptor CD4, and a small subset
of human (but notmouse) iNKT cells expresses CD8α. iNKT cells
are most abundant in spleen, liver, thymus, and bonemarrow, and
are also found in lymph nodes, peripheral blood, adipose tissue,
skin, and mucosal surfaces in the intestine and lungs. In humans,
iNKT cells are less abundant than in mice and their prevalence
varies widely among different individuals, for reasons that remain
unclear.
Following their activation iNKT cells can quickly elicit an
effector response, including rapid cytokine production and cyto-
toxicity, making them a very crucial component of the immune
response (11). Activation of iNKT cells with a cognate ligand
induces secretion of a wide variety of cytokines, chemokines, and
colony-stimulating factors. During this activation process, iNKT
cells also interact with other cells of the immune system, resulting
in their activation, recruitment, and/or differentiation (12).While
iNKT cells can simultaneously produce multiple cytokines, it is
now clear that subsets of iNKT cells producing distinct cytokines
and with distinct effector functions exist. This includes Tbet+
NKT1 cells producing IFN-γ, GATA3+ NKT2 cells producing
IL-4, RORγt+ NKT17 cells producing IL-17A, IL-21, and IL-22
(13), and Bcl6+ follicular helper NKT (NKTFH) cells producing
IL-21 (14). iNKT cells with immunosuppressive functions have
also been identified, including regulatory NKT10 cells producing
IL-10 (15), E4BP4+ regulatory iNKT cells in adipose tissue pro-
ducing IL-2 and IL-10 (16), and Foxp3+ regulatory iNKT cells
(17). Whether the latter cell types represent separate subsets of
regulatory iNKT cells remains unclear (18).
Because of their ability to produce such a mixture of cytokines
and to interact with a variety of other cells of the immune system,
iNKT cells can either promote or suppress immune responses in
different disease conditions (11, 19). They confer natural immu-
nity to cancer (20), provide protective immunity to various infec-
tious agents (3–5), generally play a suppressive role during autoim-
mune responses (18) and graft-vs.-host disease (21), and con-
tribute to the development of allergic airway reactivity (22), con-
tact hypersensitivity (23), experimental hepatitis (24), atheroscle-
rosis (25), and obesity-associated insulin resistance (26). Because
iNKT cells display such a wide variety of versatile functions, they
have been referred to as the “Swiss army knife of the immune
system” (27).
In keeping with their immunoregulatory functions, numerous
studies have explored the therapeutic activities of iNKT cells
in a variety of diseases (6–9, 11, 12). Many of these studies
have been performed with the prototypical iNKT cell antigen α-
galactosylceramide (α-GalCer), a potent iNKT cell agonist that
was originally isolated from a marine sponge (28). α-GalCer
and related glycolipids have potent anti-metastatic activities (29),
hasten clearance of some microbial pathogens (3–5), enhance the
efficacy of vaccines (30, 31), prevent graft-vs.-host disease (21),
and protect against autoimmunity in experimental models for
type 1 diabetes (32), multiple sclerosis (33), arthritis (34), and
systemic lupus erythematosus (35).
Mechanisms of iNKT Cell Activation by
Microbial Pathogens
Invariant natural killer T cells become activated in response to
challenge by a variety of microorganisms, including bacteria,
viruses, fungi, and protozoa (5). While some of these microor-
ganisms contain glycolipid or phospholipid antigens that can
bind with CD1d to activate the iNKT cell TCR, most microor-
ganisms activate iNKT cells independently of cognate antigens.
iNKT cells are highly responsive to stimulation by certain types
of cytokines, which may be induced in antigen-presenting cells
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(APCs) via engagement of pathogen recognition receptors (PRRs)
with pathogen-associated molecular patterns (PAMPs). Activa-
tion of iNKT cells via superantigens has also been reported. We
will briefly discuss these distinct modes of iNKT cell activation in
the following sections.
iNKT Cell Activation by Microbial Lipid Antigens
A number of microorganisms, especially bacteria, contain lipid
antigens that can activate iNKT cells (Figure 1A). Sphingomonas
species, which include organisms that are ubiquitous in the envi-
ronment, produce glycosphingolipids with α-linked glucuronic
or galacturonic acid (36–38), and Borrelia burgdorferi (39) and
Streptococcus pneumoniae (40) contain diacylglycerols with α-
linked glucosyl or galactosyl moieties that are recognized by
the iNKT cell TCR. Other documented or proposed iNKT cell
antigens include phosphatidylinositol mannoside from Mycobac-
terium bovis (41), a cholesterol ester with an α-linked glucoside
from Helicobacter pylori (42), an α-GalCer from the common
gut bacterium Bacteriodes fragilis (43), lipophosphoglycans from
the protozoan parasites Leishmania donovani (44) and Entamoeba
histolytica (45), and the glycosphingolipid asperamide B from the
fungal pathogen Aspergillus fumigatus (46). While most of these
antigens activate all iNKT cells, some likely activate only a subset
of iNKT cells (5). Interestingly, one study showed that B. fragilis
contains, in addition to an iNKT cell-activating α-GalCer, an
inhibitoryα-GalCer (Bf717) that regulates the homeostasis of host
intestinal iNKT cells (47).
Some of the microbial antigens, especially those derived from
Sphingomonas bacteria, bear structural similarity with α-GalCer,
the prototypical iNKT cell antigen obtained from the marine
sponge Agelas mauritianus (28). This finding led to speculation
that α-GalCer might, in fact, be derived from bacteria, possibly
Sphingomonas species, that colonize the sponge. As Sphingomonas
FIGURE 1 |Mechanisms of microbial iNKT cell activation. (A) For
microbes that contain iNKT cell antigens, such antigens may be sampled by
antigen-presenting cells (APCs) and loaded onto CD1d for presentation and
activation of iNKT cells. (B) Microbes lacking or containing iNKT cell antigens
can activate iNKT cells by innate cytokine-driven mechanisms. Microbial
products may engage pattern recognition receptors (PRRs) on APCs to
induce cytokines such as IL-12 that bind with cytokine receptors on iNKT
cells, and the production of endogenous iNKT cell antigens.
bacteria are ubiquitous in the environment, including soil and
the ocean, this is a likely yet unproven explanation for the rather
strange capacity of sponge-derived products to activate a small
subset of cells in the mammalian immune system.
While purified or synthetic versions of microbial antigens
can potently activate iNKT cells both in vitro and in vivo, the
contribution of these antigens to the response of iNKT cells to
intact microorganisms is less clear. Instead, the available evidence
suggests that innate cytokine-driven signals, rather thanmicrobial
antigens, are the main drivers of iNKT cell activation during
microbial infection (5).
Cytokine-Driven iNKT Cell Activation During
Microbial Infection
A major difference between conventional T cells and iNKT cells
is that the latter but not the former are highly responsive to innate
and cytokine-driven signals (5). iNKT cells constitutively express
a number of cytokine receptors, most notably the receptors for
IL-12 (48) and IL-18 (49). Consistent with their innate effector
functions, stimulation of iNKT cells with IL-12 or IL-18 can
induce IFN-γ production by these cells. In this context, iNKT cells
have been shown to play a critical role in the anti-tumor activities
of IL-12 (50). IL-12 has been implicated in the capacity of many
microorganisms to activate iNKT cells. This phenomenon was
initially described for Salmonella typhimurium, a Gram-negative
bacterium that lacks cognate iNKT cell antigens (51). APCs cul-
tured with this organismwere able to induce IFN-γ production by
iNKT cells, which was blocked by addition of neutralizing anti-
IL-12 antibodies. In addition to the intact microorganisms, S.
typhimurium lipopolysaccharide (LPS) similarly activated iNKT
cells in an IL-12-dependent manner, suggesting a critical role for
toll-like receptor (TLR) activation in the APCs. These findings
lead to the concept that microbes lacking cognate antigens can
activate iNKT cells in a manner that involves TLR signaling in
APCs, production of IL-12 by the APCs, and IL-12R signaling in
iNKTcells (Figure 1B). This concept has been tested and extended
to iNKT cell activation by a variety of microorganisms, including
viruses, bacteria, fungi, and protozoa (5). It was shown that TLR
ligands for either cell surface or endosomal TLRs may be involved
and, in the case of fungi, β-glucans that signal through Dectin-1
onAPCs can similarly activate iNKT cells (52).While IL-12 played
a critical role in iNKT cell activation induced by many microbes,
IL-18 was the dominant APC-derived cytokine responsible for
iNKT cell activation to LPS derived from Escherichia coli (53),
and type 1 interferons played a dominant role in the activation
of iNKT by the TLR-9 agonist CpG (54). Based on these find-
ings, a general model has emerged for the activation of iNKT
cells by microorganisms that lack cognate antigens (Figure 1B):
PAMPs activate APCs (predominantly DCs) to produce pro-
inflammatory cytokines, which, in turn, activate iNKT cells. As
already mentioned, additional evidence suggests that this might
also be the dominant pathway for iNKT cell activation by many
microbes that contain iNKT cell antigens (55).
An unusual mode of cytokine-driven iNKT cell activa-
tion was observed for hepatitis B virus (HBV) (56). HBV
induces secretory phospholipases in infected hepatocytes that
convert phosphatidylethanolamine to lysophospholipids. The
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lysophospholipids bindCD1d to activate type 2NKT (vNKT) cells
that in turn induce IL-12 production by APCs to indirectly acti-
vate iNKT cells. These findings are consistent with prior studies
providing evidence that activation of vNKT cells with cognate
antigens can lead to the trans-activation of iNKT cells (57).
A topic of some debate is whether iNKT cells themselves
express functional TLRs and, thus, might be activated directly
by PAMPs independently of APCs (5, 58). One study showed
that TCR engagement on iNKT cells can induce TLR expression,
which was able to enhance iNKT cell activation following TLR
stimulation (59). Whether direct TLR engagement on iNKT cells
contributes to their activation duringmicrobial infections remains
to be explored.
During the original studies with S. typhimurium, it was found
that iNKT cell activation in the in vitro cultures could be partially
blocked with anti-CD1d antibodies, suggesting a role for TCR
engagement on iNKT cells (51). Similar observations were made
for a number of other microbes (5, 60). These findings suggested
that microbes activate iNKT cells in a manner that involves
both cytokine receptor- and TCR-mediated signaling (Figure 1B).
However, activation of iNKT cells by some microbes such as
murine cytomegalovirus (MCMV) (61) and bymicrobial products
such as E. coli LPS (53), did not appear to require TCR signaling,
suggesting that cytokine signaling is sufficient to activate iNKT
cells during infections.
While some cytokines such as type 1 interferons can induce
CD1d expression (62), microbial infection is not always asso-
ciated with an increase in CD1d expression on APCs. In fact,
several microbes interfere with CD1d expression, presumably in
an attempt to avoid iNKT cell responses (63). Nevertheless, induc-
tion of CD1d expression on APCs might contribute to iNKT cell
activation during certain infections.
An appealing hypothesis emerging from these studies was that
microbes might induce endogenous lipid antigens for iNKT cells
(Figure 1B). This possibility was supported by the finding that
microbial products can induce enzymes involved in glycosphin-
golipid synthesis and that inhibitors of this pathway can suppress
iNKT cell activation by certain microbial products (64). Much
debate has focused on the nature of the relevant glycolipid(s)
involved.While iNKT cells potently react with α-linked but not β-
linked glycolipids, production of glycosphingolipids in mammals
has long been assumed to be limited to β-linked anomers. Nev-
ertheless, additional studies identified the β-linked glycosphin-
golipid isoglobotrihexosylceramide (iGb3) as a weak self-antigen
that was also suggested to be involved in iNKT cell activation in
response to microbial products (37, 65). Subsequent studies cast
doubt on this possibility and instead provided evidence that β-
linked glucosylceramides (β-GluCer) that accumulate in mam-
malian cells in response to microbial products are the relevant
self-antigens that synergize with APC-derived cytokines during
the activation of iNKT cells by microbial products (66). The latter
studies were predominantly performed with synthetic versions of
β-GluCer, which, as it turned out, contained minuscule amounts
of α-anomeric GluCer (67, 68). Careful studies with iNKT cell-
stimulating glycosphingolipids enriched from mammalian cells
eventually led to the conclusion that mammalian cells produce
small amounts of α-linked glycosphingolipids such as α-GalCers
and α-GluCers that can activate iNKT cells (67, 68). However,
the enzymatic pathways involved in the synthesis of these antigens
remain to be identified.
Most of the studies implicating a role of CD1d and self-antigens
in the capacity ofmicrobes or their products to activate iNKT cells
were performed in vitro. The contribution of TCR engagement
to in vivo iNKT cell activation by microbes therefore remained
unclear. Surprisingly, using a reporter mouse that can detect
TCR signaling, a recent study showed that S. typhimurium and
several TLR ligands were able to activate iNKT cells in a TCR-
independent manner (69). Therefore, these findings indicate that
many microbes can activate iNKT cells in the absence of TCR
signaling.
Superantigen-Mediated iNKT Cell Activation
Superantigens are microbial toxins that cause non-specific activa-
tion of T cells by engagingMHCclass IImolecules and the variable
region of the β-chain of the TCR. Staphylococcal enterotoxin B
(SEB) interacts with Vβ8, which is expressed by a majority of
iNKT cells. SEB was able to activate Vβ8-expressing iNKT cells
in a CD1d-independent manner (70, 71).
The in vivo Response of iNKT Cells to
Glycolipid Antigens
Most studies that have investigated the in vivo response of iNKT
cells have focused on synthetic glycolipid antigens, most notably
KRN7000, an optimized version of the original sponge-derived α-
GalCer. These studies have revealed that the in vivo response of
iNKT cells to an intraperitional injection of α-GalCer is charac-
terized by the following series of events (Figure 2) (72):
1. Prompt activation and cytokine production: α-GalCer is pre-
sented to iNKT cells predominantly by CD8α-expressing
DCs and potentially some macrophages. iNKT cell activation
involves induction of a variety of activation markers (e.g.,
CD69, CD25, and ICOS), as well as cytokine production, with
an initial burst of IL-4 (as soon as 1 h after treatment with a
peak at 4 h) followed by IFN-γ (peaks at 24 h). However, this
cytokine production gradually diminishes to very low levels at
3 days after treatment (11).
2. Cross-talk with other cell types: α-GalCer-activated iNKT
cells engage in extensive cross-talk with other immune cell
types (11). This includes activation, induction of cytokine
production (most notably IL-12), and differentiation of DCs
andmacrophages, modulation of neutrophils, recruitment and
modulation of the suppressive activities of myeloid-derived
suppressor cells, profound activation and induction of IFN-
γ production by NK cells, modulation of B cell and antibody
responses, and modulation of CD8 and CD4 T cell responses.
Most studies have provided evidence that α-GalCer treatment
promotes Th2-dominant immunity. These effects form the
basis of the immunomodulatory and therapeutic properties of
α-GalCer and other iNKT cell antigens (12).
3. TCR downregulation: quickly following their activation by α-
GalCer, iNKT cells profoundly downregulate their TCR (73).
This is due to agonist-mediated inhibition of TCR recycling to
the cell surface and makes these cells nearly undetectable by
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FIGURE 2 | Population dynamics of iNKT cells in response to glycolipid
antigen stimulation. The dynamics of the iNKT cell population in the spleen
following intraperitoneal injection of α-GalCer in mice is shown. The percentage
of iNKT cells compared with all T cells in the spleen is depicted. Injection of
α-GalCer causes alterations in a variety of surface receptors on iNKT cells,
including the invariant T cell receptor (TCR), NK1.1, and programmed death-1
(PD-1), as well as rapid cytokine production. The iNKT cell population rapidly
expands, reaching a maximum around 3days after α-GalCer treatment, after
which most of the cells undergo apoptosis to return to homeostatic levels
around 2–3weeks. These α-GalCer-experienced iNKT cells exhibit functional
defects, as revealed by their resistance to proliferate and produce large
amounts of cytokines upon α-GalCer restimulation. The phenotype of these
cells is reminiscent of anergic or regulatory cells. As indicated in the bottom of
the figure, this altered phenotype of α-GalCer-experienced iNKT cells impacts
the therapeutic activities of α-GalCer against B16 tumor metastases but not
experimental autoimmune encephalomyelitis (EAE).
staining with anti-CD3 antibodies, anti-TCR antibodies, and
CD1d-tetramers for a short time period, around 12–30 h after
treatment.
4. NK1.1 downregulation: NK1.1 downregulation starts around
24 h after treatment, making it hard to accurately detect iNKT
cells by anti-NK1.1 antibodies for an extended time period
(19, 73). NK1.1 expression slowly returns to normal levels, but
only about half of these cells express NK1.1 at 1month after
treatment.
5. Induction of the programmed death-1 receptor: programmed
death-1 (PD-1) is an inhibitory member of the CD28 family
of co-stimulatory molecules by interacting with its ligands PD-
L1 and PD-L2. PD-1 has received a lot of interest in the tumor
immunology field as a potent immune checkpoint whose
blockade can unleash anti-tumor responses. PD-1 expression
by iNKT cells is evident as early as 2–3 days after α-GalCer
treatment and is sustained for up to 2months (74–76).
6. Population expansion: iNKT cells expand in spleen and to
a lesser extent in peripheral blood, bone marrow, and liver
(73, 77). Expansion is maximal around 3 days after α-GalCer
treatment and reaches levels about 10- to 15-fold over the
starting population in spleen.
7. Apoptosis and return to homeostatic levels: following their
expansion, most iNKT cells undergo apoptosis and the iNKT
cell population returns to relatively normal homeostatic levels
around 2–3weeks after their expansion (73, 78). Apoptosis of
iNKT cells involves the pro-apoptotic Bcl-2 family member
Bim (77) and Fas/FasL interactions (79).
8. Acquisition of a hyporesponsive phenotype: as revealed by a
blunted response to α-GalCer re-injection after the initial α-
GalCer treatment, α-GalCer-experienced iNKT cells become
unresponsive to α-GalCer restimulation (19, 78). This hypore-
sponsiveness was observed in terms of reduced iNKT cell
activation (lack of induction of activation markers), blunted
proliferation and cytokine production (IFN-γ production was
more profoundly blunted than IL-4 production), and reduced
capacity to activate other cell types such as DCs and NK cells.
This hyporesponsive phenotype was evident between 3 days
and up to 2months after the original α-GalCer treatment. This
hyporesponsive phenotype of iNKT cells was largely intrinsic
to these cells and has been referred to as iNKT cell anergy. The
induction and to a lesser extent themaintenance of this anergic
phenotype involves PD-1/PD-L interactions (74–76, 80), as
well as the egr2/3 transcription factors (80), which induce
the E3 ligase Cbl-b that monoubiquitinates the CARMA1 sig-
naling molecule in the NF-κB signaling pathway (81). An
alternative explanation for the long-term effects of α-GalCer
on iNKT cells proposed more recently is that the iNKT cells
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in α-GalCer-experienced mice adopt a regulatory phenotype
with production of IL-10 (i.e., NKT10 cells) (15). Regardless
of the mechanism involved, it has been established that α-
GalCer-experienced iNKT cells exhibit impaired anti-tumor
responses but retain their capacity to protect mice against
experimental autoimmune encephalomyelitis (EAE), a mouse
model of multiple sclerosis (19).
In addition to α-GalCer, the response of iNKT cells to a variety
of other glycolipids has been investigated (11, 12). Many of these
studies have focused on the therapeutic properties of iNKT cells
and have identified glycolipid antigens that induce biased cytokine
responses in iNKT cells in attempt to enhance either their anti-
tumor activities or their protective effects against autoimmune or
inflammatory diseases. Additional studies have explored meth-
ods to prevent or overcome the altered phenotype of α-GalCer-
experienced iNKT cells. This has been accomplished by delivering
α-GalCer in the context of strong co-stimulation such as α-
GalCer-loaded DCs (19, 82), via intradermal, intranasal, or oral
rather than systemic administration (83, 84), nanoparticles (85),
recombinant CD1d molecules (86), or PD-1/PD-L blockade (74,
75, 87). Additionally, glycolipids that can potently activate iNKT
cells, yet largely lack the long-term effects on iNKT cells associated
with α-GalCer, have also been developed (88).
These methodologies to prevent induction of iNKT cell func-
tional impairments are particularly important for developing
improved iNKT cell-based therapies. Clinical studies with human
subjects have shown long-term effects of free glycolipid treatment
on human iNKT cells (89). Repeated free α-GalCer treatment
resulted in increasingly weaker biological responses, which was
consistent with the acquisition of iNKT cell dysfunction upon
α-GalCer stimulation. Interestingly, delivery of α-GalCer in the
context of DCs was able to avoid the induction of iNKT cell
dysfunction in human cancer patients (90). In this context, it is
also worth noting that several preclinical studies have shown that
the anti-metastatic activities of α-GalCer synergize with those
of PD-1/PD-L blockade (75, 87). Thus, the therapeutic activities
of iNKT cells may be enhanced by methods that prevent the
induction of activation-induced iNKT cell dysfunction.
The in vivo Response of iNKT Cells to
Microbes
Our knowledge regarding the in vivo response of iNKT cells to
glycolipid antigens has been employed as a framework to explore
the response of these cells to microbes. Most microbes and many
of their products can activate iNKT cells to express a variety
of activation markers and to induce cytokine production, with
wide effects on other immune cell types and the outcome of
the infection (5). While α-GalCer induces both IL-4 and IFN-
γ production by iNKT cells, microbes typically induce little IL-
4 production, which is consistent with the notion that most
microbes activate iNKT cells in an innate cytokine-drivenmanner
and that IL-12 promotes an IFN-γ-biased cytokine profile in these
cells.When investigated, PD-1 upregulationwas not observed, but
sustained NK1.1 downregulation was common. In sharp contrast
with α-GalCer, microbes or their products rarely induce systemic
iNKT cell expansion in vivo (as discussed below, M. bovis is an
exception), and this is true even for microbes containing iNKT
cell antigens. Nevertheless, an accumulation of iNKT cells has
been observed in some infected organs, such the lungs of mice
infected with Cryptococcus neoformans (91) and the liver of mice
infected with malaria parasites (92). A phenomenon observed for
some microbes, including systemic infection with lymphocytic
choriomeningitis virus (LCMV) (93) and L. monocytogenes (94,
95), is partial or complete iNKT cell depletion, which may last for
several weeks.
Systemic exposure to a number of microorganisms, includ-
ing E. coli, S. aureus, S. typhimurium, L. monocytogenes, and
M. bovis, has long-term effects on iNKT cell kinetics and func-
tions, resulting in a hyporesponsive phenotype reminiscent of
that observed following α-GalCer treatment (94–96). A similar
phenotype was observed for mice treated with TLR agonists such
as LPS and flagellin (95, 96). Induction of this hyporesponsive
phenotype required IL-12 expression (95), which itself does not
induce iNKT cell dysfunction and is not required for α-GalCer-
induced iNKT cell hyporesponsiveness. Furthermore, microbe-
induced iNKT cell dysfunction involved both iNKT cell-intrinsic
and -extrinsic mechanisms and was independent of the PD-1/PD-
L pathway. While α-GalCer-experienced iNKT cells exhibited
more profound defects in IFN-γ than IL-4 cytokine production,
the opposite was true for the functional alterations of iNKT
cells in response to microbes. Thus, the mechanisms involved in
the induction of iNKT cell dysfunction mediated by glycolipids
and microbes appear to be distinct. Whether specific regulatory
iNKT cell subsets expand during microbial infections has not
been explored. iNKT cells from mice systemically exposed to E.
coli exhibited impairments in their therapeutic activities against
metastatic tumors, but not in their capacity to protectmice against
EAE (95). The latter finding might have important implications
when considering iNKT cell-based therapies, as they suggest that
the functions and therapeutic activities of iNKT cells in patients
are influenced by recent infections.
A few studies have investigated the response of human iNKT
cells tomicrobial pathogens.HIV infection substantially decreases
iNKT cell numbers and functions, and this depletion was most
profound for the CD4+ subset (97–99). The reduced numbers
of iNKT cells may be due to a combination of HIV infection
and induction of apoptosis (97, 99). Interestingly, the residual
iNKT cells in infected individuals exhibited impaired ability to
proliferate and produce IFN-γ in response to α-GalCer stim-
ulation, and expressed elevated levels of PD-1 (100). Blocking
experiments indicated that these functional defects were largely
PD-1-independent (100). A similar although less profound reduc-
tion in iNKT cell numbers was observed in patients with active
M. tuberculosis infection (101). The poor response of iNKT cells
from these patients to α-GalCer was found to be due to increased
iNKT cell apoptosis and iNKT cell dysfunction. The latter was
associated with an elevated expression of PD-1, and blockade of
PD-1 signaling was able to enhance the response to α-GalCer
(101). iNKT cells were found to be activated during acute dengue
virus infection, and the level of activation was associated with dis-
ease severity (102). These cells also exhibited reduced functional
responses to subsequent α-GalCer stimulation but mechanisms
were not explored (102). These studies suggest that at least some
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of the findings obtained in mice may also apply to infections in
humans.
The response of iNKT cells tomicrobial pathogensmakes sense
from the standpoint of host–pathogen interactions. The effector
functions of iNKT cells play a critical role by influencing the
behavior of cells of the innate arm of the immune system and
to assist in the initiation and differentiation of adaptive immune
responses. Thus, iNKT cells predominantly contribute to early
immune responses and their capacity to produce cytokines should
therefore largely be limited to a relatively short time window
early in an infection. Overactivation of iNKT cells is known to
cause severe immunopathology such as liver damage (103, 104).
As iNKT cells produce large bursts of cytokines with potent pro-
inflammatory properties, the cytokine production potential of
these cells needs to be tightly controlled to avoid the generation
of a cytokine storm or a chronic inflammatory response. This may
be accomplished by inducing apoptosis or functional impairments
in these cells. One potential disadvantage of this strategy is that it
might put the host at risk for developing secondary infections with
organisms that depend on iNKT cells for protective immunity.
As responses of iNKT cells to distinct types of microbes are
quite divergent, we briefly discuss below the response of iNKT
cells to select microbial organisms.
Listeria monocytogenes
Intravenous inoculation of L. monocytogenes resulted in rapid
induction (within 1 day) of the activation marker CD69 on iNKT
cells and these cells produced IFN-γ but not IL-4 (94, 95). This
activation resulted in a gradual reduction in the number of iNKT
cells in spleen and liver. This reduction in the prevalence of
CD1d/α-GalCer-tetramer+ cells was not just due to activation-
induced downregulation of TCR expression. These cells recovered
by week 4 in the liver but not spleen. NK1.1 was downregulated
for an extended time period and closely mirrored its expression
following α-GalCer treatment. iNKT cells in L. monocytogenes-
experiencedmice showed reduced responses toα-GalCer in terms
of CD69 induction, expansion, cytokine production (with more
profound effects on IL-4 than IFN-γ), and trans-activation of DCs
and NK cells. These reduced responses were not just due to lower
numbers of iNKT cells but involved iNKT cell dysfunction, which
was present for at least 1month after infection. iNKT cells have
been shown to play a protective role in the immune response
against L. monocytogenes (105).
Mycobacterium bovis
Intravenous inoculation of M. bovis vaccine strain bacillus Cal-
mette–Guérin (BCG) causes an increase in CD69 expression on
iNKT cells by day 7, which was further increased at day 14 in both
spleen and liver (96). NK1.1 became markedly downregulated for
an extended time period. Alterations in PD-1 or CTLA-4 expres-
sion by iNKT cells were not detected. Numbers of iNKT cells
increased following infection, expanding approximately twofold
in the spleen and fivefold in the liver at 7 days after infection.
Numbers of iNKT cells subsequently contracted, reaching pre-
infection levels around 2–3weeks after infection. iNKT cell death
was associated with an increase in Fas expression on these cells.
iNKT cells were able to produce IFN-γ quickly following infection,
reaching a peak at day 7, but the capacity to produce IFN-γ quickly
waned thereafter. iNKT cells from infected animals also became
resistant to CD69 upregulation in response to α-GalCer treat-
ment. This refractory period lasted for approximately 1month.
While iNKT cell-deficient mice eliminated BCG as efficiently
as wild-type mice, these animals had more granulomas in liver
and lung, with signs of caseation, large cellular infiltrates, and
some multinucleated macrophages, which were not seen in wild-
type animals (106). These findings therefore suggested an anti-
inflammatory role for iNKT cells during BCG infection.
Lymphocytic Choriomeningitis Virus
Intraperitoneal infection of mice with the Armstrong strain of
LCMV caused a selective, long-term loss of iNKT cells in both
spleen and liver (93, 107). This apparent loss of iNKT cells was not
just due to downregulation of TCR expression. It was observed as
soon as 3 days after infection, was most profound around 10 days,
and lasted up to 3months. The dying cells expressed active cas-
pase 3, indicating apoptosis, but this process was independent of
Fas/FasL interactions. While the reasons for this sustained loss
of iNKT cells remains unclear, it has been suggested to be due
to either activation-induced cell death or direct virus infection.
Wild-type and CD1d-deficient animals cleared LCMV at similar
levels but splenocytes from CD1d-deficient animals produced
significantly higher amounts of cytokines (IL-2, IL-4, and IFN-γ),
suggesting that iNKT cells suppress the magnitude of the acute
antiviral immune response against LCMV (108).
Interaction of iNKT Cells with the
Microbiota
A microbiota is a group of microorganisms that resides in a
specific environment. The human host engages in mutualistic
relationships with commensal microbes that reside in different
parts of the body, especially the gastrointestinal tract. Recent
studies have provided evidence that iNKT cells are influenced
by the microbiota and that, conversely, iNKT cells can shape the
composition of the microbiota (109). Germ-free animals were
shown to contain increased numbers of mature, functionally
competent iNKT cells in the gut and lung as compared with
specific pathogen-free mice (110, 111). These alterations in iNKT
cells made germ-free mice more susceptible to tissue damage
and inflammation in mouse models of asthma and inflammatory
bowel disease. These effects of microbiota on iNKT cells were not
limited to mucosal surfaces, as splenic iNKT cells from germ-
free animals exhibited reduced expression of activation markers
and reduced capacity to produce cytokines. Similar findings were
made for fetal human iNKT cells (112), which develop in the
absence of microbiota. Fetal small intestinal iNKT cells were
phenotypically and functionally mature, whereas their splenic
counterparts exhibited reduced expression of activation markers.
These findings provide the intriguing possibility to manipulate
iNKT cell numbers and functions via the microbiota. The mouse
studies have shown that iNKT cells can be reprogrammed in this
manner during neonatal but not adult life.
The finding that iNKT cell numbers and functions are influ-
enced by the gut microbiota provides a potential explanation for
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some of the divergent studies that have been published in the
iNKT cell field. For example, pathogenic (113), neutral (114–117),
and suppressive (118, 119) roles of iNKT cells in the pathogenesis
of obesity-associated inflammation and insulin resistance have
been reported (26). This might be caused by differences in the
endogenousmicrobiota in the animal facilities where the different
studies were performed.
Mechanisms responsible for the effects of the microbiota on
iNKT cell numbers and functions remain unclear but may include
recognition of microbe-associated molecular patterns, microbial
metabolites, and microbial iNKT cell antigens. With regard to
the latter possibility, a provocative study showed that monocol-
onization of germ-free mice with B. fragilis can restore the colonic
iNKT cell levels (47). As mentioned above, B. fragilis contains α-
GalCers that can either activate (43) or inhibit (47) iNKT cells. The
inhibitory α-GalCer (Bf717) from this organism was able to limit
CD1d-dependent colonic iNKT cell proliferation in germ-free
mice (47).
Summary and Outstanding Questions
The studies discussed here have revealed that iNKT cells become
activated during infection by different types of pathogenic as well
as commensalmicroorganisms.While somemicroorganisms con-
tain iNKT cell ligands, their contribution to iNKT cell activation
to the intact organism remains unclear. Innate cytokine-driven
pathways play a dominant role in microbial iNKT cell activation.
iNKT cells often become activated and produce cytokines early
after microbial infection and may transiently expand, contract, or
maintain their population size. A common feature of the response
of iNKT cells to microbial infection is that it induces long-term
unresponsiveness to TCR stimulation.
Despite this progress in our understanding of the response of
iNKTcells tomicrobes, a number of outstanding questions remain
to be answered:
 What is the contribution of microbial iNKT cell antigens to
the immune response of iNKT cells to microbial pathogens?
 Do endogenous iNKT cell antigens play a role in the response
of iNKT cells to microbial pathogens in vivo?
 What are the molecular mechanisms responsible for the
long-term effects of distinct microbes and their products on
the numbers and functions of iNKT cells?
 Can commensal microorganisms or their glycolipid antigens
be employed to reprogram iNKT cell functions in humans?
 How do themechanisms responsible for microbial iNKT cell
activation relate to those that mediate iNKT cell activation
during sterile inflammation?
 How similar are the mechanisms that control iNKT cell
activation in response to microbes in mice and humans, and
how do they differ?
 How can this information be employed for the development
of improved iNKT cell-based therapies?
These questions will provide rich and fertile avenues for future
investigations.
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